Brief: Theravance Biopharma Q3 Loss Per Share $0.48

Theravance Biopharma

03/11/2021 22:31

Nov 3 (Reuters) - Theravance Biopharma Inc  TBPH.O :
    * THERAVANCE BIOPHARMA, INC. REPORTS THIRD QUARTER 2021
FINANCIAL
RESULTS AND PROVIDES BUSINESS UPDATE
    * THERAVANCE BIOPHARMA INC - TRELEGY Q3 2021 GLOBAL NET
SALES:
$449 MILLION, UP 77% FROM Q3 2020
    * THERAVANCE BIOPHARMA INC - RESTRUCTURING PROCEEDING
ACCORDING TO
PLAN
    * THERAVANCE BIOPHARMA INC - REITERATES THAT IT EXPECTS FULL
YEAR
2021 RESEARCH AND DEVELOPMENT EXPENSE OF $180 MILLION TO $190
MILLION
    * THERAVANCE BIOPHARMA INC - QTRLY LOSS PER SHARE $0.48

Source text for Eikon:  ID:nPn1hJZ9ya 
Further company coverage:  TBPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))